What is Glioblastoma Multiforme (GBM) - recurrent, multifocal - how to think about staging? Do the records state this

Let me analyze this specific document and provide information about GBM staging while incorporating authoritative sources.

From the Document: The clinical summary shows that Alan has:

• Primary diagnosis: Glioblastoma Multiforme (GBM)
• Current status: Recurrent and multifocal disease
• Multiple locations involved: "corpus callosum, bilateral hemispheres (left > right), right frontal area, left temporal region with posterior insular involvement"
• New 10mm enhancing nodule in left frontal area
• Evidence of intratumoral bleeding

Regarding Staging: According to the National Cancer Institute (NCI) and National Comprehensive Cancer Network (NCCN) Guidelines, GBM doesn't use the traditional TNM staging system. Instead, the key prognostic factors include:

1. Initial vs. Recurrent Disease:

• The document clearly shows this is recurrent disease with first recurrence in May 2024
• Multiple recurrences are documented with "multifocal progression"

1. Molecular Markers:

• The document notes "Molecular testing data not specified in available records"
• According to NCCN Guidelines, molecular markers like IDH mutation status and MGMT methylation are crucial for prognosis and treatment planning
• The summary recommends "Urgent molecular profiling if not already completed"

1. Disease Extent: According to ASCO Guidelines, key considerations for recurrent GBM include:

• Number of lesions (document shows multiple sites)
• Location of tumors (document shows bilateral involvement)
• Presence of complications (document notes seizures and bleeding)

The document demonstrates this is an advanced case based on:

• Multifocal recurrence
• Rapid progression ("new lesions developing every 3 months")
• Treatment resistance ("TMZ ineffective")

Sources:

• NCCN Guidelines for Central Nervous System Cancers
• ASCO Guidelines for Treatment of Adult Glioblastoma
• National Cancer Institute's GBM Classification System